Literature DB >> 19898560

c-Ski, Smurf2, and Arkadia as regulators of TGF-beta signaling: new targets for managing myofibroblast function and cardiac fibrosis.

Ryan H Cunnington1, Mansoreh Nazari, Ian M C Dixon.   

Abstract

Recent studies demonstrate the critical role of the extracellular matrix in the organization of parenchymal cells in the heart. Thus, an understanding of the modes of regulation of matrix production by cardiac myofibroblasts is essential. Transforming growth factor beta (TGF-beta) signaling is transduced through the canonical Smad pathway, and the involvement of this pathway in matrix synthesis and other processes requires precise control. Inhibition of Smad signaling may be achieved at the receptor level through the targeting of the TGF-beta type I receptors with an inhibitory Smad7/Smurf2 complex, or at the transcriptional level through c-Ski/receptor-Smad/co-mediator Smad4 interactions. Conversely, Arkadia protein intensifies TGF-beta-induced effects by marking c-Ski and inhibitory Smad7 for destruction. The study of these TGF-beta mediators is essential for future treatment of fibrotic disease, and this review highlights recent relevant findings that may impact our understanding of cardiac fibrosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19898560     DOI: 10.1139/Y09-076

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  19 in total

Review 1.  Proteasome dysfunction in cardiomyopathies.

Authors:  Jennifer E Gilda; Aldrin V Gomes
Journal:  J Physiol       Date:  2017-03-16       Impact factor: 5.182

Review 2.  New molecular medicine-based scar management strategies.

Authors:  Anna I Arno; Gerd G Gauglitz; Juan P Barret; Marc G Jeschke
Journal:  Burns       Date:  2014-01-15       Impact factor: 2.744

3.  Silencing of c-Ski augments TGF-b1-induced epithelial-mesenchymal transition in cardiomyocyte H9C2 cells.

Authors:  Jia Ling; Zhenrong Cai; Wei Jin; Xiaohua Zhuang; Lihong Kan; Fei Wang; Xiaolei Ye
Journal:  Cardiol J       Date:  2018-03-23       Impact factor: 2.737

4.  Atrial fibrillation induces myocardial fibrosis through angiotensin II type 1 receptor-specific Arkadia-mediated downregulation of Smad7.

Authors:  Xuyu He; Xiuren Gao; Longyun Peng; Shenming Wang; Yingying Zhu; Hong Ma; Jun Lin; Dayue Darrel Duan
Journal:  Circ Res       Date:  2010-12-02       Impact factor: 17.367

5.  Inhibitory effect of tanshinone II A on TGF II-β1-induced cardiac fibrosis.

Authors:  Daixing Zhou; Zhihui Li; Liwei Zhang; Chengye Zhan
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-12-28

6.  Deficiency of biglycan causes cardiac fibroblasts to differentiate into a myofibroblast phenotype.

Authors:  Ariane Melchior-Becker; Guang Dai; Zhaoping Ding; Liliana Schäfer; Jürgen Schrader; Marian F Young; Jens W Fischer
Journal:  J Biol Chem       Date:  2011-03-18       Impact factor: 5.157

7.  Integrative analysis reveals essential mRNA, long non-coding RNA (lncRNA), and circular RNA (circRNA) in paroxysmal and persistent atrial fibrillation patients.

Authors:  Haoliang Sun; Junjie Zhang; Yongfeng Shao
Journal:  Anatol J Cardiol       Date:  2021-06       Impact factor: 1.596

8.  Spatiotemporal delivery of basic fibroblast growth factor to directly and simultaneously attenuate cardiac fibrosis and promote cardiac tissue vascularization following myocardial infarction.

Authors:  Zhaobo Fan; Zhaobin Xu; Hong Niu; Yang Sui; Haichang Li; Jianjie Ma; Jianjun Guan
Journal:  J Control Release       Date:  2019-09-12       Impact factor: 9.776

9.  SnoN residue (1-366) attenuates hypertrophic scars through resistance to transforming growth factor-β1-induced degradation.

Authors:  Gui-Fang Sun; Hong-Chang Li; Yue-Ping Zhan; Xiao-Fen Zhang; Li-Yun Pan; Ya-Feng Chen; Ke Xu; Dian-Xu Feng
Journal:  Lab Invest       Date:  2019-08-13       Impact factor: 5.662

Review 10.  Novel therapeutic strategies targeting fibroblasts and fibrosis in heart disease.

Authors:  Robert G Gourdie; Stefanie Dimmeler; Peter Kohl
Journal:  Nat Rev Drug Discov       Date:  2016-06-24       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.